Get the Stockscreener App
171.49
0.63%
-1.08
After Hours:
171.00
-0.49
-0.29%
Astrazeneca Plc stock is traded at $171.49, with a volume of 3.67M.
It is down -0.63% in the last 24 hours and up +5.00% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$172.57
Open:
$171.28
24h Volume:
3.67M
Relative Volume:
1.13
Market Cap:
$265.96B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
51.50
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+3.68%
1M Performance:
+5.00%
6M Performance:
-10.82%
1Y Performance:
+2.81%
1-Day Range:
$169.51
$171.75
1-Week Range:
$163.91
$173.91
52-Week Range:
$153.41
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
171.49 | 265.96B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,273.46 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.81 | 635.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.64 | 504.76B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.27 | 358.41B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.12 | 287.24B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-26 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Jul-13-26 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
AstraZeneca Launches Targeted Lung Cancer Drug In US After FDA Accelerated Approval - Yahoo Finance
Summit Expands Ivonescimab Development Into Biliary Tract Cancer - Zacks Investment Research
AstraZeneca, Abu Dhabi Biobank to Explore AI Platform for Disease Prediction - www.marketscreener.com
AstraZeneca bags another US indication for Ultomiris with IgAN approval - Yahoo Finance
P&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards - Yahoo Finance
AstraZeneca Wins FDA Accelerated Approval for Ultomiris in Rare Kidney Disease - AskTraders.com
AstraZeneca says U.S. FDA approves rare kidney disease drug By Investing.com - Investing.com Nigeria
AstraZeneca says FDA approves drug for rare kidney disease in adults - www.marketscreener.com
AstraZeneca says FDA approves drug for rare kidney disease in adults - Reuters
Is AstraZeneca (AZN) Stock Cheap? - Yahoo Finance
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story? - Yahoo Finance
AstraZeneca PLC : Gets a Buy rating from JP Morgan - marketscreener.com
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research
Biotech ETF (BBH) Hits New 52-Week High - Zacks Investment Research
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - The Motley Fool
Positive Results for an AstraZeneca and Amgen Product - marketscreener.com
Amgen, AstraZeneca Detail Phase III Data For Tezspire’s Likely Third Indication - Scrip
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study - Benzinga
AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple? - Yahoo Finance
AstraZeneca partners with Oracle for AI-driven clinical trials - Reuters
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Reuters
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Jefferies puts AstraZeneca kidney drug trial success odds at 59% - Proactive financial news
AstraZeneca and Oracle strike AI collaboration to speed up clinical trials - Seeking Alpha
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology - Zacks Investment Research
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month - Zacks Investment Research
Astrazeneca (AZN) Rises Higher Than Market: Key Facts - Zacks Investment Research
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research
The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk - Zacks Investment Research
Top Research Reports for Mastercard, AstraZeneca & Sandisk - Zacks Investment Research
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? - Zacks Investment Research
AstraZeneca reports HICKORY Phase III results for AstraZeneca stock - ad-hoc-news.de
AstraZeneca Summit Deal: What Does Completion Unlock? - Kalkine Media
AstraZeneca PLCAmerican Depositary Shares (NYSE:AZN) Stock Quote - FinancialContent
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint - Yahoo Finance
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual MeetingSlideshow (NYSE:AZN) 2026-10-12 - Seeking Alpha
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi - Proactive financial news
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal - Benzinga
AstraZeneca pins bone disease drug’s Phase III failure on high placebo response - Clinical Trials Arena
Weekly Recap: U.S. $50B expansion and Summit stake funding ivonescimab - TradingView
AstraZeneca PLC (AZN) stock price, news, quote and history - Yahoo Finance Australia
ASTRAZENECA PLC CEDEAR EA RE 0. (AZND.BA) Q1 FY2026 earnings call transcript - Yahoo Finance
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth? - Yahoo Finance
AstraZeneca falls Thursday, underperforms market - MarketWatch
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Astrazeneca Plc Stock (AZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sharma Mani | See Remarks |
May 20 '26 |
Sale |
185.78 |
11,893 |
2,209,482 |
19,262 |
3.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):